Men on Active Surveillance for Prostate CA May Benefit From 5-ARI Use
Men who take 5-alpha-reductase inhibitors while on active surveillance for prostate cancer are less likely to experience cancer progression, according to a new study
Benign Prostatic Hyperplasia
BPH Medications May Increase Heart Failure Risk
It is important for urologists and primary care physicians to be aware of the potential link between BPH medications and heart failure risk, according to investigators.
Certain Prostate Drugs Tied to Risk for Parkinson Disease
Use of glycolysis-enhancing drugs terazosin, doxazosin, or alfuzosin tied to lower risk for developing Parkinson disease than use of tamsulosin
Adding Vibegron to BPH Meds Safe, Effective for Overactive Bladder
In a small study, add-on vibegron appeared well-tolerated and clinically effective among men with persistent OAB.
Disproportionality Signal Found for Suicidality in Finasteride Users
Younger patients and those with alopecia have significant disproportionality signals for increased suicidality
Risk for T2DM Increased With Use of 5α-Reductase Inhibitors
Increased risk seen among men using dutasteride, finasteride for benign prostatic hyperplasia
Finasteride Not Tied to Increase in Prostate Cancer Mortality
Finasteride is not associated with an increased risk for death due to prostate cancer, according to a research letter published in the New England Journal of Medicine.
Bethanechol Prescribing Patterns Examined in Women With Bladder Dysfunction
While bethanechol, a cholinergic agonist, may “theoretically” improve detrusor contractility in women with underactive bladder (UAB), the evidence supporting its use is limited.
Mortality Risk Compared Among Men Receiving Drug Therapy for BPH/LUTS
Researchers conducted a retrospective matched cohort study to compare the risk of death among BPH patients treated with 5ARIs, as monotherapy or in combination with alpha-blockers, and those treated with alpha-blockers alone.
AUA Updates Castration-Resistant Prostate Cancer Clinical Guideline
“We are confident this guideline is fully aligned with the latest science on treatments for patients with non-metastatic and metastatic CRPC,” said Michael Cookson, MD, member of the 2018 amendment panel.
